During the past decade, INTEGRIS conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "INTEGRIS" #1 sponsor was "Gilead Sciences" with 2 trials, followed by "Bayer" with 1 trials sponsored, "Northwestern University" with 1 trials sponsored, "The University of Texas Health Science Center, Houston" with 1 trials sponsored and "University of Michigan" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "INTEGRIS" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator and "Xcenda, LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "INTEGRIS" are "Heart Failure" (2 trials), "Hypertension" (2 trials), "Cardiovascular Diseases" (1 trials), "Congestive Heart Failure" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "INTEGRIS" in a lesser frequency.

Most popular intervention types in "INTEGRIS" are "Drug" (5 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Darusentan" (2 trials), "Adenosine" (1 trials), "Contrast Media" (1 trials), "Dapagliflozin 10 MG" (1 trials) and "Darusentan Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "INTEGRIS" are 7 trials for "All" genders.

Currently, there are NaN active trials in "INTEGRIS". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in INTEGRIS, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in INTEGRIS, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".